CAY10704 is a potent inhibitor of hepatitis C virus (HCV) infection (EC
50 = 17 nM) that displays low cytotoxicity of virally-infected human hepatoma Huh7.5.1 cells (CC
50 = 21.3 μM).
1 It displays good pharmacokinetics in mice when delivered intraperitoneally, with preferential liver distribution without significant hepatotoxicity.
1 CAY10704 is selective for HCV over dengue virus (EC
50 = 4.62 μM).
1
1. He, S., Xiao, J., Dulcey, A.E., et al. Discovery, optimization, and characterization of novel chlorcyclizine derivatives for the treatment of hepatitis C virus infection J. Med. Chem. 59(3),841-853(2016).
